Under the terms of the agreement, Stem Cell Sciences (SCS) will provide research services, cell lines, media and reagents to support Pfizer’s R&D efforts in this important field.
Alastair Riddell, CEO of SCS, said: “The opening of Pfizer’s new regenerative medicine research facility in Cambridge, UK, is very important for stem cell research and reinforces the UK’s position as an international centre of excellence. We are therefore very pleased to be able to support Pfizer’s efforts to advance biomedical research under our new agreement.”